Skip to main content
main-content

14-02-2021 | ASCO GU 2021 | Conference coverage | Video

EV-201: Enfortumab an option for cisplatin-ineligible advanced UC

Arjun Balar reports on EV-201 results suggesting that cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer may benefit from treatment with enfortumab vedotin after checkpoint inhibitor therapy (4:14).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

Read transcript

Image Credits